Clinical Trial Update: Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating a vaccine therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF) with or without low-dose aldesleukin i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Aldesleukin (interleukin-2)
• GM-CSF (granulocyte-macrophage colony-stimulating factor)

Snippet

Sponsor: Mayo Clinic | Conditions: Melanoma (Skin) | Phase 1 | Status: COMPLETED